Table 1.

US FDA-approved prescription omega-3 fatty acid products indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia

Brand name	Generic name	EPA contenta	DHA contenta	Dosing/administration	Adverse reactions in clinical trials
Vascepa	Icosapent ethyl	1 g	None	4 g/day (2 capsules bid) with food	Arthralgia,b oropharyngeal pain
Lovazac	Omega-3-acid ethyl esters	~0.465 g	~0.375 g	4 g/day (4 capsules od or 2 capsules bid) with or without food	Eructation,d dyspepsia,d taste perversion,d constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash
Epanovae	Omega-3-carboxylic acids	0.55 g	0.2 g	2 g or 4 g/day (2 or 4 capsules od). In clinical trials, administration took place without regard to meals	Diarrhea,d nausea,d abdominal pain or discomfort,d eructation,d abdominal distension, constipation, vomiting, fatigue, nasopharyngitis, arthralgia, dysgeusia
Omtryg	Omega-3-acid ethyl esters A	~0.465 g	~0.375 g	4 g/day (4 capsules od or 2 capsules bid) with food	Eructation,d dyspepsia,d taste perversion,d constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash

ALT alanine aminotransferase, AST aspartate aminotransferase, bid twice daily, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, GI gastrointestinal, od once daily

^aPer capsule

^bIncidence ≥2 % and >placebo

^cGeneric formulations of Lovaza are available

^dIncidence ≥3 % and >placebo

^eEpanova is approved but not available at the time of the writing of this review